New cocktail of drugs shows promise for rare, aggressive tumors
NCT ID NCT06232564
First seen Jan 26, 2026
Summary
This phase II trial is testing a combination of chemotherapy (carboplatin and etoposide) with immunotherapy (pembrolizumab), followed by maintenance therapy with pembrolizumab and lenvatinib, in 20 people with advanced high-grade neuroendocrine tumors who have not had prior chemotherapy. The goal is to see if this approach can shrink tumors and improve outcomes. The study is active but no longer recruiting participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Imperial College Healthcare NHS Trust
London, W12 0HS, United Kingdom
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pembrolizumab, carboplatin, etoposide, and lenvatinib
What this could lead to
If successful, this could offer a new treatment option that shrinks tumors and delays progression for people with advanced high-grade neuroendocrine tumors.
What could go wrong
This is a small, early-phase trial with only 20 participants, so results may not apply to everyone. The combination of drugs can cause significant side effects, and it's unclear if it will work better than current treatments.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.